Leading CDMO is Granted Both the Worldstar Award for Vetter-Ject® and a 2016 CMO Leadership Award
News Feb 19, 2016
The World Packaging Organization (WPO) has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the WorldStar Award 2016 for its syringe closure system Vetter-Ject®. The WorldStar competition is one of the major events of the WPO, and its award represents the pre-eminent international award in packaging.
Vetter has now won four internationally recognized awards for a product only released in July 2015. Two of the awards, won prior to the products launch, include the IF Design Award, and the Red Dot Design Award. Recently, Vetter-Ject® won the “German Packaging Award 2015”.At the same time, Vetter is proud to have also been awarded a CMO Leadership Award 2016 in four categories.
The WorldStar competition is open to any pack or packaging material that has won a recognized or domestic international award related to packaging in either 2014 or 2015. Winning of the German Packaging Award 2015 assured Vetter’s submission to the WorldStar competition.
Representatives from 19 packaging associations judged 293 projects entered into the competition from 35 countries. The judging session took place over 2 days in October, 2015 as part of the 95th WPO Board Meeting activities. Vetter had previously won the WorldStar award in 1998 for the Vetter Lyo-Ject® dual chamber syringe.
“The winning of this award, certainly one of the most prestigious in the field of global packaging, is very gratifying to Vetter, and yet another affirmation of the value that Vetter-Ject® brings to the biopharmaceutical industry,” said Dr. Claus Feussner, Senior Vice President, Vetter Development Service. “The three awards we had already received, combined with the WorldStar Award, are a validation of the novel design and technological advances of Vetter-Ject®.” Since its introduction in July, Vetter has had positive feedback both from the market and our customers about this system.
Pharmaceutical and biotech companies are increasingly developing drugs that incorporate sensitive and complex compounds. Administering these drugs requires an injection system that can be used flexibly while being safe and simple to handle. Vetter-Ject® is such a system, consisting of a needle hub and a needle shield. Due to the baked-in siliconization process for the glass barrel, less silicon oil than commonly used is necessary, making Vetter-Ject® particularly suitable for silicone-sensitive drug products.
The silicon content of the syringe can also be adjusted according to the requirements of the customer. Thus, the amount of silicon used; as well as the related particle load, can be reduced by up to 80% when compared to the standard siliconization process applied to conventional syringe systems.
Vetter-Ject® is ready-to-use with an integrated needle that is simple to handle and user-friendly. The tamper-evident closure enables that any attempt at opening of the closure system will be immediately and permanently visible to the naked eye. Vetter-Ject® can be used with a wide range of primary packaging options like different stoppers and glass barrels, which can be customized according to the needs of the drug product.
The efficient vetting of potential CMO partners is a difficult experience for pharmaceutical and biopharmaceutical executives. To assist in this process, Life Science Leader magazine created the CMO Leadership Awards. More than 80 contract manufactures were assessed by 26 performance metrics in Industry Standard Research’s (ISR) annual Contract Manufacturing Quality Benchmarking survey. For 2016, Vetter was named the winner in four categories including, quality, capabilities, expertise, and compatibility.
“Vetter is pleased to be a recipient of this award, particularly since it is a direct reflection of our customers’ experience in having worked right alongside us,” said Peter Soelkner, Managing Director. “Their nomination and the granting of the award is a clear indication to Vetter that we continue to exceed the expectations of our peers in areas of critical importance to their business.
Unlike other industry awards that are based on a subjective voting or nomination process, only votes from companies that have cooperated on an outsourced project within the past 18 months in using CMO services are counted.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE